BrightGene Bio Medical Technology C (688166) — Strategic Asset Allocation Index
BrightGene Bio Medical Technology C (688166) has a Strategic Asset Allocation Index of 97.1% as of June 2023. Strategic assets (PP&E of CN¥2.29 Billion plus long-term investments of CN¥-) total CN¥2.29 Billion, measured against net assets of CN¥2.35 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check BrightGene Bio Medical Technology C asset resilience ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
BrightGene Bio Medical Technology C Strategic Asset Allocation Index (2016–2022)
This chart shows how BrightGene Bio Medical Technology C's Strategic Asset Allocation Index has evolved across 7 annual periods from 2016 to 2022. As of June 2023, the index stands at 97.1%, representing strategic assets of CN¥2.29 Billion against net assets of CN¥2.35 Billion CNY. See 688166 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for BrightGene Bio Medical Technology C (2016–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for BrightGene Bio Medical Technology C from 2016 to 2022, covering 7 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see how much is BrightGene Bio Medical Technology C worth.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 92.6% | CN¥2.08 Billion | CN¥2.08 Billion | CN¥- | CN¥2.24 Billion | ▲ +13.5 pp |
| 2021 | 79.1% | CN¥1.38 Billion | CN¥1.38 Billion | CN¥- | CN¥1.74 Billion | ▲ +47.6 pp |
| 2020 | 31.6% | CN¥452.50 Million | CN¥452.50 Million | CN¥- | CN¥1.43 Billion | ▲ +13.0 pp |
| 2019 | 18.6% | CN¥244.69 Million | CN¥244.69 Million | CN¥- | CN¥1.31 Billion | ▼ -10.0 pp |
| 2018 | 28.7% | CN¥221.59 Million | CN¥221.59 Million | CN¥- | CN¥772.85 Million | ▼ -5.2 pp |
| 2017 | 33.9% | CN¥151.20 Million | CN¥151.20 Million | CN¥- | CN¥446.02 Million | ▼ -26.8 pp |
| 2016 | 60.7% | CN¥133.59 Million | CN¥133.59 Million | CN¥- | CN¥220.15 Million | — |